globenewswire

Explore the latest insights into the global construction industry with our comprehensive report. Discover market size, growth forecasts to 2029, and a breakdown of residential and non-residential segments. Analyze competitive pressures and key financials of top players, underpinning informed business strategies.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PepGen To Contact Him Directly To Discuss Their Options

The global adrenal crisis market is witnessing significant growth driven by increasing adrenal insufficiency recognition and rising adrenal crisis incidents. The expanding global prevalence of autoimmune diseases and corticosteroid use for chronic conditions further accelerates market demand. However, challenges such as high treatment costs, limited awareness in low-income regions, and diagnostic complexities may slow adoption in emerging markets. Between 2025-2035, advancements in diagnostic technologies and innovative therapies are expected to bolster market growth, though access issues remain crucial. Key players like Eton Pharmaceuticals, Antares Pharma, and Pfizer are leading with product innovation and strategic partnerships.

VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, today reacts to the July 10, 2025 new policy directive from Secretary of Defense Pete Hegseth, ‘Unleashing U.S. Military Drone Dominance.’ ZenaTech confirms that under this policy directive, its entire portfolio of ZenaDrone drones qualify as Group 1–2 expendable assets and are now enabled for direct purchases by field commanders for both training and real-world missions, and they no longer need Green or Blue UAS (Unmanned Aerial System) certification.

SINGAPORE, July 11, 2025 (GLOBE NEWSWIRE) -- The cryptocurrency market is in the midst of an explosive bull run, with Bitcoin recently breaking the $110,000 mark, sparking excitement and renewed interest among traders and investors globally. As the digital asset class continues to mature, BexBack Exchange is capitalizing on this surge by offering unrivaled trading conditions to both new and seasoned crypto traders.

Award Recognition underscores the importance of AI-driven drug discovery

– Absence of neurotoxicity of any grade in low-volume disease to-date –

MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone^® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 31,500,000 of its common shares (the “Shares”), accompanying Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 31,500,000 common shares and accompanying Series B common warrants (the “Series B Common Warrants”) to purchase an aggregate of 31,500,000 common shares , at a combined public offering price of $1.50 per share and accompanying Series A Common Warrant and Series B Common Warrant and (ii) in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase 3,502,335 common shares, accompanying Series A Common Warrants to purchase an aggregate of 3,502,335 common shares and accompanying Series B Common Warrants to purchase an aggregate of 3,502,335 common shares, at a combined public offering price of $1.499 per pre-funded warrant and accompanying Series A Common Warrant and Series B Common Warrant, which represents the combined public offering price for the Shares and accompanying common warrants less the $0.001 per share exercise price for each such pre-funded warrant. The proceeds to Milestone from the Offering, before deducting underwriting commissions and offering expenses payable by Milestone, are expected to be approximately $52.5 million. The Offering is expected to close on or about July 14, 2025, subject to satisfaction of customary closing conditions.

Discover the definitive U.S. Cereal Manufacturing Industry analysis with projections reaching $17.97 billion by 2031. Access historical data, revenue forecasts, and key benchmarks. Ideal for financial analysts, M&A advisors, and consultants. Includes metrics for top companies like General Mills and Kellogg.

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

CHENNAI, India, July 11, 2025 (GLOBE NEWSWIRE) -- Sify Technologies Limited (NASDAQ: SIFY), India’s leading Digital ICT solutions provider with global service capabilities spanning Data Center, Cloud, Networks, Security and Digital services, today announced that it will report its unaudited IFRS financial results for the First quarter ended June 30, 2025 on Friday, July 18, 2025 before the market opens.